{"question": "What has the medtech industry achieved?", "answer": "The medtech industry has had a tremendous impact on society and improved quality of life for billions.", "rating": 8}
{"question": "What challenges has the medtech industry faced in recent years?", "answer": "The medtech industry has faced unprecedented challenges due to the lasting impact of the COVID-19 pandemic, macroeconomic and geopolitical uncertainties, and stagnating shareholder returns.", "rating": 9}
{"question": "What is the main focus of the report 'Medtech Pulse: Thriving in the next decade'?", "answer": "The report seeks to provide insights and perspectives to inform the journey ahead for medtech leaders, starting with a look at shifting the value creation equation and how it influences medtech\u2019s next act.", "rating": 8}
{"question": "What are some of the key topics discussed in the report?", "answer": "The report discusses topics such as reimagining R&D, software innovation, bringing hardware and software together into digital health ecosystems, and updating the post-COVID-19 playbook for M&A.", "rating": 9}
{"question": "What is the significance of ESG strategy for medtech companies?", "answer": "An environmental, social, and governance (ESG) strategy is an untapped opportunity for medtech companies to differentiate their devices.", "rating": 8}
{"question": "How many years have medtech advancements added to US life expectancy since 1980?", "answer": "Five years.", "rating": 8}
{"question": "What percentage of the US population is estimated to have medical devices implanted in their bodies?", "answer": "10 percent.", "rating": 8}
{"question": "How many people are employed by medtech companies around the world?", "answer": "More than two million people.", "rating": 8}
{"question": "At what rate have prices for medical devices increased since 2009 compared to the broader medical consumer price index?", "answer": "One-seventh the rate.", "rating": 7}
{"question": "What is the estimated size of the medtech industry in 2023?", "answer": "Nearly $600 billion.", "rating": 8}
{"question": "What is the expected annual growth rate of the medtech industry through 2026?", "answer": "5 to 6 percent.", "rating": 9}
{"question": "How many types of medical devices have medtech companies created for patients and caregivers around the world?", "answer": "More than two million.", "rating": 8}
{"question": "By how many years has US life expectancy increased since 1980 due to medtech advancements?", "answer": "Five years.", "rating": 9}
{"question": "What percentage of the US population is estimated to have medical devices implanted in their bodies?", "answer": "10 percent.", "rating": 9}
{"question": "How many people are employed by medtech companies around the world?", "answer": "More than two million.", "rating": 8}
{"question": "At what rate have prices for medical devices increased since 2009 compared to the broader medical consumer price index?", "answer": "One-seventh the rate.", "rating": 7}
{"question": "What is the estimated size of the medtech industry in 2023?", "answer": "Nearly $600 billion.", "rating": 8}
{"question": "What is the projected annual growth rate of the medtech industry through 2026?", "answer": "5 to 6 percent.", "rating": 9}
{"question": "How many types of medical devices have medtech companies created for patients and caregivers around the world?", "answer": "More than two million.", "rating": 8}
{"question": "How did medtech perform compared to the S&P 500 in the 2012\u201319 period?", "answer": "Medtech outperformed the S&P 500 by nearly twofold.", "rating": 9}
{"question": "How did Medtech perform compared to the S&P 500 in the 2012\u201319 period?", "answer": "Medtech outperformed the S&P 500 by nearly twofold.", "rating": 9}
{"question": "What has happened to valuation multiples for the highest-growth medtech companies since 2019?", "answer": "Valuation multiples for the highest-growth companies have been more than halved.", "rating": 9}
{"question": "What is required for medtech to create value for patients and shareholders over the next decade?", "answer": "Another industry reinvention, with a bias toward transformation, not incremental improvement.", "rating": 8}
{"question": "What are the top medtech focus areas of innovation, according to Exhibit 1?", "answer": "Cardiovascular and cerebrovascular diseases (31%), oncology (16%), and nervous system diseases (19%).", "rating": 8}
{"question": "What percentage of unmet need is attributed to cardiovascular and cerebrovascular diseases?", "answer": "34%.", "rating": 8}
{"question": "What are some examples of 'premium innovation' in medtech?", "answer": "New, minimally invasive treatments such as transcatheter technologies and remote-monitoring solutions.", "rating": 9}
{"question": "What has been the trend in R&D spending in the medtech industry since 2019?", "answer": "R&D spending has accelerated, growing at twice the rate of industry sales since 2019.", "rating": 9}
{"question": "How have clinical-trial volumes changed from 2015 to 2023?", "answer": "Clinical-trial volumes remained flat from 2015 to 2019, but are now growing at 11 percent annually.", "rating": 9}
{"question": "What was the relationship between novel product approvals and shareholder returns from 2017 to May 2023?", "answer": "Companies in the top quartile of novel product approvals saw shareholder returns almost twice as high as those in the second and third quartiles (and four times higher than those in the bottom quartile).", "rating": 9}
{"question": "How did the medtech industry perform compared to the S&P 500 in the 2010s?", "answer": "Medtech outpaced the S&P 500 in the 2010s.", "rating": 8}
{"question": "What has happened to the slow-growth portion of the medtech market since 2012?", "answer": "The slow-growth portion of the market has doubled since 2012.", "rating": 8}
{"question": "What should companies do with resources dedicated to incremental innovation?", "answer": "Companies should apply more scrutiny to resources dedicated to incremental innovation and consider if a business without 'premium' innovation has a role in the portfolio of the future.", "rating": 9}
{"question": "Why are medtech companies struggling to engage with newer sites of care?", "answer": "To date, medtech companies, especially non-large-cap companies, have struggled to engage newer sites of care.", "rating": 7}
{"question": "What is happening to the growth rate of general acute-care facilities?", "answer": "According to McKinsey analysis, general acute-care facilities, medtech's largest customer segment, are projected to see slower growth than almost all other healthcare provider types.", "rating": 9}
{"question": "What challenges are medtech companies facing in the European market?", "answer": "The European Union Medical Device Regulation (EU MDR) has introduced new costs, such as postlaunch surveillance requirements, and hospital-level tendering and contracting policies are increasing the commercial investment needed to serve European healthcare providers.", "rating": 9}
{"question": "What is the trend in US healthcare provider profit pools?", "answer": "Hospital profits are shifting to alternate care settings, with virtual-care and home-care providers expected to increase their share of the overall US healthcare provider profit pool from 4% in 2017 to 15% in 2027.", "rating": 9}
{"question": "What should medtech company leaders do regarding their global growth strategies?", "answer": "Company leaders should take action to clarify their global intentions and tailor their strategies to specific geographic regions, including reassessing commercial models, increasing or reducing investment, and considering local acquisitions to foster profitable growth.", "rating": 9}
{"question": "Where are hospital profits shifting to, according to Exhibit 3?", "answer": "Alternate care settings, such as virtual-care and home-care providers, specialist offices, and ambulatory-care centers.", "rating": 8}
{"question": "What percentage of the overall US healthcare provider profit pool is expected to be held by general acute-care facilities in 2027?", "answer": "38%", "rating": 8}
{"question": "What is one way medtech companies are changing the care paradigm and realizing better outcomes?", "answer": "By competing intelligently in digital ecosystems that marry capital products with technology.", "rating": 7}
{"question": "What is an example of a successful digital solution in medtech?", "answer": "AI-based clinical decision making, fueled by device data, which has become an integral part of many spine and general surgery procedures.", "rating": 9}
{"question": "How are successful medtech companies handling investments during the current period of uncertainty?", "answer": "By making trade-offs and committing at scale to a handful of investments that will drive performance in the long term.", "rating": 8}
{"question": "What action should medtech company leaders take to foster profitable growth?", "answer": "Reassessing commercial models, increasing or reducing investment, and considering local acquisitions.", "rating": 8}
{"question": "Why did the company shut down its new offering?", "answer": "The company made the bold choice to shut down the new offering while committing to commercial innovation, which provided immediate cost savings, accelerated growth, and delivered the benefit of clarity.", "rating": 7}
{"question": "What should companies do during periods of uncertainty?", "answer": "Companies should perform a detailed review of ongoing investments and use this period of uncertainty to commit to the handful that will drive performance in the long term.", "rating": 9}
{"question": "What has happened to the operating margins of medtech companies as of the first quarter of 2023?", "answer": "The operating margins for medtech companies are 200 to 400 basis points lower than they were in 2021, returning to mid-2010s levels.", "rating": 9}
{"question": "What is the current paradigm for value creation in the medtech industry?", "answer": "In investors' eyes, companies' chances to beat current growth expectations are low, given that the industry has already doubled its growth rate in the past ten years.", "rating": 8}
{"question": "What has happened to the correlation between profit margin and medtech valuations since 2019?", "answer": "The correlation between profit margin and medtech valuations has more than doubled.", "rating": 8}
{"question": "What should medtech companies do to boost long-term value creation?", "answer": "Along with investing in growth, companies should also consider profitability programs as ways to boost long-term value creation.", "rating": 8}
{"question": "What is foundational for sustainable business growth in medtech?", "answer": "R&D and product development excellence are foundational for sustainable business growth in medtech.", "rating": 9}
{"question": "What is the average percentage of revenue invested in R&D by the largest global medtech companies?", "answer": "8 percent.", "rating": 9}
{"question": "How many patent applications were filed by medtech companies at the European Patent Office in 2021?", "answer": "About 15,000.", "rating": 8}
{"question": "What percentage of medtech projects are developed on time and on budget?", "answer": "About 35 percent.", "rating": 8}
{"question": "What is the trend in the average number of US FDA approvals per billion dollars spent since 2011?", "answer": "The average number of US FDA approvals per billion dollars spent has declined by an average of 9 percent per year.", "rating": 9}
{"question": "What are the four areas of focus associated with delivering value-creating innovation in medtech R&D?", "answer": "A systematic approach to portfolio management, empowered product managers and strong system-engineering capabilities, adoption of agile principles and use of next-generation digital and analytical tools, and outward orientation (e.g., working with open development networks).", "rating": 10}
{"question": "How much of the variation in companies' growth rates is accounted for by average R&D spending in the previous three years?", "answer": "About 1.6 percent.", "rating": 8}
{"question": "What has happened to the average number of FDA approvals per $ billion of R&D spending in the medtech industry over time?", "answer": "The average medtech company has achieved fewer device approvals relative to R&D spending over time, with a decline of 9% per annum.", "rating": 9}
{"question": "What are the five areas critical for R&D excellence according to the text?", "answer": "Although the text doesn't explicitly list the five areas, it mentions that medtech companies that outperform their counterparts take a holistic approach to R&D transformation, tackling in parallel five areas critical for R&D excellence, with one of them being a systematic approach to portfolio management.", "rating": 7}
{"question": "What is a characteristic of companies with effective R&D portfolio management systems?", "answer": "Companies with effective R&D portfolio management systems have formalized R&D portfolio management processes and a strong decision-making culture in which top management is deeply committed and engaged.", "rating": 9}
{"question": "Why is determining what not to do important in R&D portfolio management?", "answer": "Determining what not to do is as crucial as deciding what to pursue because it allows organizations to terminate projects that fail or struggle to advance or those whose business cases have weakened due to changes in the market.", "rating": 9}
{"question": "What did a senior executive at a large global medtech company achieve in three years?", "answer": "The organization doubled the value of the company\u2019s pipeline R&D projects and multiplied the number of high-value R&D projects (as measured by net present values) in three years.", "rating": 8}
{"question": "What is the ultimate purpose of R&D organizations in medtech companies?", "answer": "Delivering world-class products, technologies, and services to healthcare providers and patients.", "rating": 8}
{"question": "What are the three 'power capabilities' required to define world-class products?", "answer": "Product management, design thinking, and systems engineering.", "rating": 8}
{"question": "What is the role of product managers in medtech companies?", "answer": "To act as business owners for their respective products, requiring a comprehensive set of skills, particularly in leadership and influencing, and a strong understanding of unmet customer needs.", "rating": 9}
{"question": "How did medtech companies that led the industry in adopting best design practices perform compared to the average competitor?", "answer": "They had 42 percent higher revenue growth and 108 percent higher shareholder returns.", "rating": 9}
{"question": "What is the role of systems engineering in R&D organizations?", "answer": "To translate users' unmet needs and requirements into actionable product architectures and technical specifications for entire systems and their components.", "rating": 9}
{"question": "What approach do medtech companies that outperform their counterparts take to R&D transformation?", "answer": "A holistic approach, tackling in parallel five areas critical for R&D excellence.", "rating": 8}
{"question": "What is the role of a strong system-engineering function in product development?", "answer": "A strong system-engineering function effectively translates users\u2019 unmet needs and requirements into actionable product architectures and technical specifications for entire systems and their components.", "rating": 9}
{"question": "How can agile development practices impact time to market and productivity in medtech R&D?", "answer": "Agile development practices can reduce time to market by more than 30 percent and increase productivity by about 20 percent.", "rating": 9}
{"question": "How should agile development be applied in medtech R&D?", "answer": "Agile development needs to be applied in the unique context of medtech R&D, tailored to work in between the typical stage gates of R&D necessary for quality assurance and regulatory compliance.", "rating": 9}
{"question": "What is the benefit of embedding quality in the development process from the outset?", "answer": "Embedding quality in the development process from the outset and testing at each development stage can cut in half the time it takes to generate design history files (DHF), a requirement for regulatory approval.", "rating": 9}
{"question": "When do medtech companies draw the most benefit from agile practices?", "answer": "Medtech companies draw the most benefit from agile practices when used in concert with other core agile principles, such as small cross-functional teams and daily rituals.", "rating": 8}
{"question": "How have next-generation digital and analytical tools impacted development cycle times and costs in other industries?", "answer": "Next-generation digital and analytical tools have reduced development cycle times by more than 50 percent and reduced costs by 30 percent in other industries.", "rating": 8}
{"question": "By how much have next-generation digital and analytical tools reduced development cycle times in other industries?", "answer": "More than 50 percent.", "rating": 8}
{"question": "How much did a medical equipment R&D organization cut its development timeline after adopting new software?", "answer": "From 12 to 18 months to six months.", "rating": 9}
{"question": "What was the result for a medtech company that used advanced analytics to improve R&D productivity?", "answer": "It reduced its R&D costs by 10 percent and increased throughput by 15 percent.", "rating": 9}
{"question": "How did a medtech company use digital tools to address a severe adverse event in a human implant?", "answer": "The R&D team used a digital twin and a deep-learning model to rapidly simulate and validate hundreds of potential alternate designs.", "rating": 9}
{"question": "What percentage of their product development pipeline do pharmaceutical companies derive from external partners?", "answer": "Up to 50 percent.", "rating": 8}
{"question": "What are some external sources that medtech companies could consider accessing for ideas, talent, and technologies?", "answer": "Original development manufacturers, joint development manufacturers, joint ventures, strategic alliances, and corporate venture funds.", "rating": 9}
{"question": "What is one approach medtech companies can take for development efforts that fall outside their core businesses and competencies?", "answer": "Spin off the venture, find co-investors to scale it, and reintegrate it into the parent company later.", "rating": 8}
{"question": "What are the benefits of a new venture being freed from corporate decision making?", "answer": "The new venture can move more quickly, has access to a larger pool of capital from investors with a higher-risk appetite, and can maintain a strong strategic and operational focus.", "rating": 9}
{"question": "How can medtech companies improve their R&D function?", "answer": "Rewiring the function could help make it not only a source of innovation but also an engine for commercial growth.", "rating": 7}
{"question": "What is the new role of software in medtech?", "answer": "Software is taking on a new, expanded role in medtech, becoming a value-adding differentiator and even being the device itself in some cases.", "rating": 8}
{"question": "What are the top constraints for software development in medtech according to the medtech R&D roundtable survey?", "answer": "The top constraints are related to operating models\u2014team capacity, skills, and talent\u2014not technology or demand.", "rating": 9}
{"question": "What three actions can medtech companies take to improve their operating model for software R&D?", "answer": "Build a robust tech stack, adopt software development best practices, and strategically source intellectual property and talent.", "rating": 9}
{"question": "What is the purpose of the engagement layer in a tech stack?", "answer": "The engagement layer is the software's connection to the outside world, ensuring the ability to integrate reliably and securely with partners through APIs.", "rating": 9}
{"question": "What is the function of the intelligence layer in a tech stack?", "answer": "The intelligence layer harnesses algorithms and seamlessly aggregates data from proprietary and publicly available sources.", "rating": 8}
{"question": "What are the three layers of a robust tech stack?", "answer": "The engagement layer, the intelligence layer, and the infrastructure layer.", "rating": 9}
{"question": "What is the primary function of the engagement layer?", "answer": "The engagement layer is the software's connection to the outside world (other devices and data sources).", "rating": 9}
{"question": "What is the role of the intelligence layer?", "answer": "The intelligence layer harnesses algorithms and aggregates data from proprietary and publicly available sources.", "rating": 9}
{"question": "What are the top constraints faced by medtech companies in developing software as a medical device?", "answer": "Capacity of R&D team, skills or talents needed, profitability costs and profitability, unclear or complicated and long regulatory process, lack of management decisions, and technology constraints.", "rating": 8}
{"question": "Why are algorithms important in medtech?", "answer": "Algorithms make decisions that influence patient care and outcomes, and effective algorithms can quickly differentiate companies from one another.", "rating": 9}
{"question": "What has been the impact of cloud on the infrastructure layer?", "answer": "The advent of cloud has led to consumption-driven pricing models that lower barriers to entry, replacing the traditional model that required large, onetime investments in data centers.", "rating": 9}
{"question": "How should medtech companies approach building a tech stack for the cloud?", "answer": "Medtech companies should build a new tech stack tailored for the cloud rather than simply retrofitting their existing tech stack.", "rating": 9}
{"question": "What is the key to successful software development in medtech?", "answer": "Adopting software development best practices, such as rethinking product management and rapidly iterating with customers, product managers, and product developers.", "rating": 9}
{"question": "How do product managers within medtech organizations typically interact with R&D?", "answer": "Their interactions with R&D often involve rigid, legacy documentation of market and product requirements rather than more collaborative problem-solving sessions.", "rating": 8}
{"question": "What are the two characteristics of great product managers in medtech companies?", "answer": "First, they carefully track usage data and draw on it to know their customers, shape the product road map, determine when to retire products, and enable users to capture value more quickly. Second, they have an impeccable 'product sense' with an intuitive ability to understand how technology can address an issue in a new way.", "rating": 9}
{"question": "What benefits can companies achieve by increasing the productivity of engineers, teams, and the whole organization?", "answer": "Companies can save 15 to 30 percent in IT operating expenditures, accelerate time to market tenfold, and achieve 55 percent higher innovation from self-organizing, agile teams.", "rating": 9}
{"question": "What are the four phases companies can act in to fully unlock velocity and deliver innovation to the front lines quickly?", "answer": "The diagnostic phase, the blueprint phase, the frontrunner phase, and the scaling phase.", "rating": 8}
{"question": "Why is cybersecurity important for medtech manufacturers, and what potential benefit can it bring?", "answer": "Cybersecurity is important because medtech manufacturers are handling sensitive patient data, a relatively new concept. Companies that develop leading cybersecurity practices and prove themselves to be trusted partners could gain a competitive advantage.", "rating": 9}
{"question": "What is a potential competitive advantage for medtech manufacturers handling sensitive patient data?", "answer": "Companies that develop leading cybersecurity practices and prove themselves to be trusted partners could gain a competitive advantage.", "rating": 8}
{"question": "What is a major concern for medtech executives regarding software product development?", "answer": "Whether their organizations can harness the benefits of software product development\u2014including agility and rapid iterative cycles\u2014in a highly regulated industry.", "rating": 9}
{"question": "According to Exhibit 2, what are the four software development drivers that have the greatest impact on overall business performance?", "answer": "The four drivers are: 1. Culture, 2. Tools, 3. Product management, and Talent management is also among the top, along with another driver from the remaining options (e.g., Security and compliance, Team characteristics, etc.), though the exact four are not explicitly listed, Culture and Tools are among the top with 7.5% and 6.4% relative importance respectively.", "rating": 7}
{"question": "What is 'branching' in software development, as mentioned in the text?", "answer": "Tiering software features within a given product and tailoring their development accordingly, with highly regulated features following one branch of the development pathway and less-regulated features following another branch.", "rating": 9}
{"question": "According to a VP of product development at a top five global medtech company, what is a major issue with their product teams?", "answer": "Their inability to gather nonfunctional requirements, which is a major source of compliance and quality issues.", "rating": 9}
{"question": "What percentage of software code was released using a continuous integration and continuous delivery pipeline by a medtech services and product company?", "answer": "20 percent.", "rating": 8}
{"question": "What strategy have companies used to manage highly regulated and less-regulated software features?", "answer": "Branching: tiering software features within a given product and tailoring their development accordingly.", "rating": 9}
{"question": "What was the outcome for a large medtech company after dedicating three months to categorizing its software products and developing tailored branches?", "answer": "The company was able to frequently update the user interface of less-stringent software elements based on user feedback and maintain compliance.", "rating": 9}
{"question": "What was identified by a council of leading medtech CIOs and CTOs as the most significant inhibitor of growth and innovation?", "answer": "The shortage of good technical software talent.", "rating": 8}
{"question": "According to Exhibit 3, what is the relationship between the percentage of digital and analytics employees and growth potential?", "answer": "Companies with a higher percentage of digital and analytics employees have higher growth potential.", "rating": 8}
{"question": "How did a global medtech company increase its appeal to graduating students?", "answer": "By engaging one-on-one and sharing the mission and role in reshaping the pandemic.", "rating": 7}
{"question": "What is the estimated total addressable market for medtech companies in digital health ecosystems by 2025?", "answer": "$140 billion.", "rating": 9}
{"question": "What is the expected growth rate of the total addressable market for medtech companies in digital health ecosystems?", "answer": "Double-digit CAGR.", "rating": 8}
{"question": "What are the five areas across which the $140 billion opportunity for medtech companies in digital health ecosystems is spread?", "answer": "Clinical-decision enablement, workflow improvement, population health monitoring, chronic-condition management, and patient engagement.", "rating": 9}
{"question": "What have medical devices become, following the lead of other technologies?", "answer": "Smaller, lighter, safer, and sturdier.", "rating": 8}
{"question": "What is the next frontier for medical devices?", "answer": "To make devices smarter.", "rating": 8}
{"question": "What is the relationship between the percentage of digital and analytics employees and the growth potential of medtech companies?", "answer": "Companies with a higher percentage of digital and analytics employees have higher growth potential.", "rating": 8}
{"question": "What is the estimated total addressable market for medtech companies in digital health ecosystems by 2025?", "answer": "$140 billion", "rating": 7}
{"question": "What are the five areas across which the opportunity for medtech companies in digital health ecosystems is spread?", "answer": "clinical-decision enablement, workflow improvement, population health monitoring, chronic-condition management, and patient engagement", "rating": 9}
{"question": "What are the three technology layers that comprise a device-driven digital health ecosystem?", "answer": "engagement, intelligence, and infrastructure", "rating": 9}
{"question": "What is the role of the engagement layer in a device-driven digital health ecosystem?", "answer": "to support flexible collaboration with other devices and sources in an ecosystem to curate an end-to-end experience for users", "rating": 9}
{"question": "What are the two main roles that medtech leaders will need to decide for their company in device-driven digital health ecosystems?", "answer": "Builder and Orchestrator", "rating": 8}
{"question": "What is the primary function of a Builder in a device-driven digital health ecosystem?", "answer": "to construct a new ecosystem business to provide diversified offerings that constitute a break with tradition", "rating": 9}
{"question": "What is the primary function of an Orchestrator in a device-driven digital health ecosystem?", "answer": "to help connect companies in an ecosystem by developing strategic partnerships and alliances and using digital technology to link them", "rating": 9}
{"question": "What are the three layers of an ecosystem built around a medical device?", "answer": "The three layers are: 1) Engagement layer, 2) Intelligence layer, and 3) Infrastructure layer.", "rating": 8}
{"question": "What is the role of an orchestrator in a healthcare ecosystem?", "answer": "An orchestrator helps connect companies in an ecosystem by developing strategic partnerships and alliances and using digital technology to link them together.", "rating": 9}
{"question": "What role do most medtech companies play in ecosystems today?", "answer": "Most medtech companies today act as participants in ecosystems.", "rating": 8}
{"question": "How does ResMed's AirSense machine interact with other components of its ecosystem?", "answer": "ResMed's AirSense machine connects to its myAir app and AirView, a provider-facing platform, to improve patient monitoring and feed data back to ResMed.", "rating": 9}
{"question": "What is an example of a medtech company that plays the builder role in an ecosystem?", "answer": "Johnson & Johnson's Abiomed is an example of a medtech company that plays the builder role with Impella Connect, a smartphone app that allows healthcare professionals to monitor a patient's status.", "rating": 9}
{"question": "What are the benefits of playing the participant role in an ecosystem for a medtech company?", "answer": "Playing the participant role can create loyalty to a company's device beyond a discrete use and offer the opportunity to collect additional data and glean new insights.", "rating": 8}
{"question": "What is the role of Abiomed in the ecosystem with Impella Connect?", "answer": "Abiomed plays the builder role with Impella Connect.", "rating": 8}
{"question": "What is Impella Connect used for?", "answer": "Impella Connect is a smartphone app that allows healthcare professionals and Abiomed's clinical support team to monitor a patient's status without having to sit at their bedside.", "rating": 9}
{"question": "How does the Impella Connect ecosystem improve patient care?", "answer": "The ecosystem improves patient care by sending notifications when urgent care is needed and enables collaborative patient management between the Abiomed support team and clinicians.", "rating": 9}
{"question": "What is the difference between open and closed ecosystems?", "answer": "Open ecosystems integrate and share data and insights to and from other devices and systems, while closed ecosystems are more self-contained and have limited input and output to other devices or systems.", "rating": 10}
{"question": "When is an open ecosystem more suitable?", "answer": "An open ecosystem is more suitable when several products and data components are required to get a holistic view of the patient's condition.", "rating": 9}
{"question": "What type of devices are more likely to have a closed ecosystem?", "answer": "Devices that are self-contained and require limited input and output to other devices or systems, such as cardiac-rhythm management devices.", "rating": 9}
{"question": "What are some examples of devices that have open ecosystems?", "answer": "Examples include sleep apnea and continuous glucose monitoring devices.", "rating": 8}
{"question": "What are some examples of devices that have closed ecosystems?", "answer": "Examples include cardiac-rhythm management devices, robotic systems, energy-based devices, and smart instruments.", "rating": 9}
{"question": "What type of ecosystem relies on collaboration from different partners?", "answer": "An open ecosystem.", "rating": 7}
{"question": "Why can closed ecosystems be difficult to maintain?", "answer": "Because competitors are often offered incentives to interject their products and services.", "rating": 8}
{"question": "How do open and closed ecosystems vary?", "answer": "Based on device type and reliance on data.", "rating": 7}
{"question": "What type of devices are associated with open ecosystems?", "answer": "Devices with complex adherence patterns, requiring physician monitoring and output to other devices or systems of record.", "rating": 9}
{"question": "What are some examples of devices associated with open ecosystems?", "answer": "Sleep apnea and continuous glucose monitoring.", "rating": 8}
{"question": "What type of devices are associated with closed ecosystems?", "answer": "Devices in a self-contained care pathway that require limited input and output to other devices or systems.", "rating": 9}
{"question": "What are some examples of devices associated with closed ecosystems?", "answer": "Cardiac-rhythm management, robotic systems, energy-based devices, and smart instruments.", "rating": 9}
{"question": "Is the notion of open versus closed ecosystems always binary?", "answer": "No, it is not always binary; this decision might vary across the three technical layers to create an optimal structure.", "rating": 9}
{"question": "What are the three technical layers across which the decision to be open or closed might vary?", "answer": "Engagement, Intelligence, and Infrastructure.", "rating": 9}
{"question": "What is the critical design principle that medtech companies need to evaluate when it comes to ecosystems?", "answer": "The choice between open and closed, overall and within each ecosystem layer.", "rating": 9}
{"question": "What is the critical design principle that medtech companies need to evaluate when building ecosystems?", "answer": "The choice between open and closed, overall and within each ecosystem layer.", "rating": 9}
{"question": "What are the two primary ways medtech companies can monetize ecosystems?", "answer": "Stand-alone revenue and pull-through device value.", "rating": 8}
{"question": "What is a closed ecosystem in the context of medtech?", "answer": "A closed ecosystem is one in which users rely exclusively on data and services from a company\u2019s device or devices.", "rating": 9}
{"question": "What determines whether companies can generate stand-alone software or SaaS revenue tied to the ecosystem offering?", "answer": "The additional value they bring to the ecosystem and care pathway, beyond what is already delivered by the primary device.", "rating": 9}
{"question": "Why might a medtech company choose a closed ecosystem?", "answer": "To deliver unique benefits to users, such as generating more accurate and insightful data, and to create a higher likelihood that patients will use the company's device.", "rating": 9}
{"question": "What are the two primary revenue streams that drive ecosystem business models?", "answer": "Stand-alone revenue (software and SaaS) and device pull-through.", "rating": 10}
{"question": "What is the estimated total addressable market (TAM) for ecosystem revenue streams by 2025?", "answer": "$140\u2013$150 billion.", "rating": 9}
{"question": "How much of the total addressable market is attributed to stand-alone revenue?", "answer": "$90 billion.", "rating": 8}
{"question": "What is required for companies to generate stand-alone software or SaaS revenue tied to the ecosystem offering?", "answer": "The additional value they bring to the ecosystem beyond what is already delivered by the primary device.", "rating": 8}
{"question": "How can medtech companies monetize their ecosystems?", "answer": "By producing and capturing large volumes of high-quality data, and potentially receiving subscription revenues from third-party developers for access to their ecosystem.", "rating": 9}
{"question": "What is the first strategy consideration for medtech companies to launch or advance ecosystem initiatives?", "answer": "Define value concretely and connect it to the user\u2019s economic model.", "rating": 9}
{"question": "What are the different roles that medtech companies can play in an ecosystem, in order of value derived?", "answer": "Builders, orchestrators, and participants, with builders deriving the most value and participants still deriving significantly more value than nonparticipants.", "rating": 9}
{"question": "What is required for medtech companies to capture the opportunity in a timely manner?", "answer": "Medtech companies need to be realistic about their potential.", "rating": 7}
{"question": "How do successful ecosystems generate value?", "answer": "Successful ecosystems generate positive reinforcement, both for the users they engage and in the value they create.", "rating": 8}
{"question": "What happens as more users engage with an ecosystem that uses patient-reported outcomes to inform clinical-decision-making tools?", "answer": "More data is generated, which can lead to better clinical decisions, enticing more users into the ecosystem.", "rating": 9}
{"question": "What is the expected outcome for companies that build, orchestrate, or participate in device-driven digital ecosystems?", "answer": "They are well positioned to deliver distinct impact to patients and providers and to create new value for shareholders.", "rating": 8}
{"question": "What is happening to medtech customers' expectations after three years of digital communication?", "answer": "Medtech customers, including healthcare professionals, health system procurement departments, and health system administrators, have higher expectations of their engagements with medtech companies.", "rating": 9}
{"question": "What has been the trend in SG&A spend as a percentage of sales for major medtech companies from 2019 to 2022?", "answer": "SG&A spend shrank as a percentage of sales for the first time since the Great Recession.", "rating": 7}
{"question": "What is the main challenge medtech companies are facing in terms of their commercial models?", "answer": "Medtech companies are facing challenges as their commercial models must evolve to support new types of offerings, adapt to changing customer expectations, and position companies to succeed in the decade ahead.", "rating": 9}
{"question": "What has happened to medtech customers' expectations after three years of digital communication?", "answer": "After three years of digital communication, medtech customers\u2014including healthcare professionals (HCPs), health system procurement departments, and health system administrators\u2014have higher expectations of their engagements with medtech companies.", "rating": 9}
{"question": "How have medtech companies responded to the trend of digital engagement?", "answer": "Medtech leaders have started to respond to this trend by augmenting the traditional commercial model with additional roles and channels to provide seamless, convenient, personalized, and on-demand engagement, including self-service portals, webinars, and social media content.", "rating": 9}
{"question": "What is the current preference of HCPs regarding interaction with medtech sales reps?", "answer": "More than two-thirds of HCPs prefer email interaction with medtech sales reps today, compared with less than half in 2019.", "rating": 8}
{"question": "What percentage of medtech leaders reported that their companies have not laid out a customer-centric vision?", "answer": "Two-thirds of medtech leaders reported that they had not laid out a customer-centric vision.", "rating": 8}
{"question": "What has happened to SG&A spend as a percentage of sales for major medtech companies from 2019 to 2022?", "answer": "SG&A spend shrank as a percentage of sales for the first time since the Great Recession.", "rating": 8}
{"question": "What trend has been observed in HCPs' preference for interacting with medtech sales representatives?", "answer": "HCPs' preference for digital and remote interactions with companies has continued to grow, with more than two-thirds preferring email interaction with medtech sales reps today, compared with less than half in 2019.", "rating": 9}
{"question": "Why are HCPs increasingly preferring digital interactions with medtech representatives?", "answer": "Severe staff shortages, which leave HCPs with even less time for in-person interactions with medtech representatives, are accelerating this trend.", "rating": 8}
{"question": "What is becoming a necessity for medtech companies?", "answer": "Omnichannel engagement\u2014creating a unified customer experience across multiple channels with the requisite investments in people, processes, and technology\u2014is quickly becoming a necessity for medtech companies.", "rating": 9}
{"question": "What is associated with improved business performance in medtech companies?", "answer": "Omnichannel engagement is associated with improved business performance.", "rating": 8}
{"question": "What is the relationship between omnichannel maturity and business performance according to Exhibit 1?", "answer": "Omnichannel maturity is associated with stronger business performance and faster post-pandemic recovery.", "rating": 9}
{"question": "Why are health systems increasingly expressing a desire to shift their spending toward subscription-based offerings?", "answer": "Facing financial pressures, health systems are increasingly expressing a desire to shift their spending away from large capital purchases and toward subscription-based, as-a-service (XaaS) offerings.", "rating": 10}
{"question": "What is the trend in health systems' spending on medtech products?", "answer": "Health systems are increasingly expressing a desire to shift their spending away from large capital purchases and toward subscription-based, as-a-service (XaaS) offerings.", "rating": 10}
{"question": "What is the effect of adopting XaaS models on medtech companies?", "answer": "Companies that have adopted XaaS models have seen improved shareholder value, and capital markets tend to reward medtech companies that show strong growth of new business models and services.", "rating": 9}
{"question": "What is the benefit of investing in omnichannel capabilities for medtech companies?", "answer": "Medtech companies that invested in omnichannel capabilities experienced two to three times higher revenue growth than their less-advanced industry peers.", "rating": 9}
{"question": "What are the three layers of capabilities in a next-generation commercial model?", "answer": "The three layers are: 1) Master the basics, 2) Personalize omnichannel engagement, and 3) Harness the power of ecosystem selling.", "rating": 9}
{"question": "What is the first step in revamping a commercial model for medtech leaders?", "answer": "Medtech commercial leaders can start by identifying the most strategic customer stakeholder groups and their beliefs, motivations, unmet needs, and desired buying processes.", "rating": 9}
{"question": "What is the first step for medtech commercial leaders to start their strategy?", "answer": "Identifying the most strategic customer stakeholder groups and their beliefs, motivations, unmet needs, and desired buying processes.", "rating": 8}
{"question": "How can medtech commercial leaders augment their research?", "answer": "With data-backed insights including claims data analysis to estimate procedure volumes at different hospitals.", "rating": 8}
{"question": "What are the three layers of capabilities in a next-generation commercial model?", "answer": "1. Master the basics, 2. Personalize omnichannel engagement, and 3. Harness the power of ecosystem selling.", "rating": 9}
{"question": "What is involved in 'Master the basics' layer of capabilities?", "answer": "Deploying digital and inside sales channels, adopting routines for customer segmentation and account planning, and pricing processes followed and measured on an ongoing basis.", "rating": 9}
{"question": "What is the purpose of adopting a customer-relationship-management (CRM) system?", "answer": "To holistically understand and address account and customer needs.", "rating": 8}
{"question": "What is the goal of 'Personalize omnichannel engagement' layer?", "answer": "To create a true omnichannel experience by seamlessly putting together multiple engagement channels and delivering a meaningful customer experience.", "rating": 9}
{"question": "What is the first step to create a true omnichannel experience for medtech companies?", "answer": "Lay a stable, reliable foundation.", "rating": 7}
{"question": "What is required to deliver a meaningful customer experience in an omnichannel engagement?", "answer": "A deep understanding of the customer and designing journeys that align with customer preferences and can be adapted based on customer actions and behaviors.", "rating": 9}
{"question": "Who has an integral role to play in leading the transformation to omnichannel engagement?", "answer": "Sales leaders and their teams.", "rating": 8}
{"question": "What is dynamic deal scoring used for?", "answer": "To assess deal quality in real time using advanced analytics.", "rating": 9}
{"question": "What is the role of a dedicated customer experience group in omnichannel engagement?", "answer": "To study and identify optimal ways to engage with customers based on their day-to-day activities and behaviors, and measure customer responses to various efforts.", "rating": 9}
{"question": "What are some moments that can act as an impetus to redesign customer journeys with omnichannel?", "answer": "Launching a first-in-class product, launching a second-to-market product with room for growth, enabling procedure innovation, and entering a new care setting or customer segment.", "rating": 8}
{"question": "What moments can act as an impetus to redesign customer journeys with omnichannel?", "answer": "Launching a first-in-class product, launching a second-to-market product with room for growth, enabling procedure innovation (new standards of care), and entering a new care setting or customer segment.", "rating": 9}
{"question": "What is required to address the right customers at the right time with the right personalized message?", "answer": "Building data science capabilities.", "rating": 7}
{"question": "How can data insights and model outputs inform marketing campaigns?", "answer": "Data insights and model outputs can inform marketing campaigns that fill the top of the sales funnel, such as through common marketing automation tools.", "rating": 9}
{"question": "What is necessary for evolving commercial models for a digital-first future?", "answer": "Creating and capturing value beyond core medical products.", "rating": 8}
{"question": "What new roles are required for the commercial organization to evolve for XaaS models?", "answer": "Digital talent and reps skilled in XaaS selling.", "rating": 8}
{"question": "What is the purpose of assembling a dedicated customer experience group?", "answer": "To study and identify the optimal ways to engage with customers based on their day-to-day activities and behaviors and measure customer responses to various efforts.", "rating": 9}
{"question": "What new roles are required for a commercial organization to evolve for ecosystem selling?", "answer": "New roles such as digital talent and reps skilled in XaaS selling are required.", "rating": 8}
{"question": "What was the result of one company's efforts to revamp its commercial organization and processes for ecosystem selling?", "answer": "Combined deals tripled in value compared with a legacy product deal or purely digital deal.", "rating": 9}
{"question": "Why did the company create an overlay sales structure?", "answer": "Because the decision-makers for the company's XaaS products and solutions are fundamentally different from those who make decisions for legacy products.", "rating": 9}
{"question": "What is a RACI matrix used for?", "answer": "A RACI matrix is a diagram that identifies the roles and responsibilities of individuals at each point along the customer journey.", "rating": 8}
{"question": "How can a medtech company drive commercial growth through digital solutions?", "answer": "By offering algorithmic decision-support solutions using a machine's test results in an 'installation fee plus subscription' model.", "rating": 8}
{"question": "What are the key considerations for building a winning medtech commercial model?", "answer": "Considerations span people, process, and technology, including software-selling talent, customer success organization, as-a-service pricing, and omnichannel capabilities.", "rating": 9}
{"question": "What are the three layers of a commercial model for the medtech industry's next act?", "answer": "Foundational practices propel resilience, omnichannel keeps the customer experience at the center, and ecosystem selling is the force multiplier in a digitally powered future.", "rating": 9}
{"question": "What is required to propel the evolution of commercial capabilities in medtech?", "answer": "Commercial leaders need to articulate a compelling vision, find champions to reinforce the vision, and publicly celebrate small successes to create buy-in and support adoption.", "rating": 9}
{"question": "What are the key considerations for building a winning medtech commercial model?", "answer": "Considerations span people, process, and technology, including factors such as software-selling talent, as-a-service pricing, data scientists, and real-time data collection technology.", "rating": 8}
{"question": "What is the role of operations functions in the medtech industry?", "answer": "Operations functions allow an idea in an R&D lab to translate to patient impact, at scale, by handling tasks from procurement of raw materials to final delivery of products to end customers.", "rating": 8}
{"question": "What is the benefit of a new solution for instrument and reagent sales?", "answer": "The new solution gives it an edge over competitor instruments, driving sales.", "rating": 7}
{"question": "What is the main challenge medtech companies face as they emerge from the COVID-19 pandemic?", "answer": "Medtech leaders are scrutinizing operations to find ways to better serve patients and bolster competitiveness.", "rating": 8}
{"question": "What role do operations functions play in the medtech industry?", "answer": "Operations functions allow an idea in an R&D lab to translate to patient impact, at scale.", "rating": 9}
{"question": "How did medtech companies respond to the COVID-19 pandemic?", "answer": "Manufacturing organizations mobilized to more than quintuple the US national stockpile of ventilators.", "rating": 8}
{"question": "What is the potential consequence for medtech companies that struggle with operations as devices become more complex?", "answer": "They will find themselves mired in increasing complexity.", "rating": 7}
{"question": "What is one way medtech companies can rethink their operations to become more reliable and profitable?", "answer": "Rebuilding supply chains with resilience as a new priority.", "rating": 8}
{"question": "How often does a supply shock lasting more than two months occur on average, according to the McKinsey Global Institute?", "answer": "Every 3.7 years.", "rating": 9}
{"question": "What is the first step medtech leaders can take to build supply chain resilience?", "answer": "Gaining real-time, end-to-end visibility into the supply chain.", "rating": 9}
{"question": "What is a challenge medtech companies face in capturing the value of digitalization and Industry 4.0?", "answer": "Capturing that value enterprise-wide remains a challenge.", "rating": 8}
{"question": "What was the result of a leading medical-device company digitalizing its planning function?", "answer": "The company realized a 15 percent increase in forecast accuracy and recaptured $60 million from inventory improvement.", "rating": 9}
{"question": "What approach should medtech companies use to advance innovation and unlock substantial top-line and bottom-line value?", "answer": "A cross-functional, customer-centric design-to-value (DtV) approach.", "rating": 9}
{"question": "What is the potential margin increase that applying a structured DtV approach could achieve?", "answer": "15 to 40 percent.", "rating": 9}
{"question": "Over a ten-year period, what percentage of one year's earnings could supply shocks cost the average medtech company?", "answer": "38 percent.", "rating": 9}
{"question": "Why is procurement becoming increasingly important for leaders in medtech companies?", "answer": "Even before the recent spike in inflation, procurement had become increasingly important for leaders.", "rating": 7}
{"question": "What percentage of total cost of goods sold for medical-device products do direct material costs typically represent?", "answer": "50 to 70 percent.", "rating": 9}
{"question": "By how much can medtech companies increase their margins by applying a structured Design to Value (DtV) approach?", "answer": "15 to 40 percent.", "rating": 9}
{"question": "What reduction in external spending have medtech companies achieved within 18 to 24 months by investing in procurement excellence?", "answer": "10 to 15 percent.", "rating": 9}
{"question": "What is the typical year-over-year savings achieved by medtech companies that invest in procurement excellence?", "answer": "4 to 5 percent.", "rating": 9}
{"question": "How does the procurement maturity of medtech companies compare to other industries like consumer products and automotive?", "answer": "Medtech companies lag behind other industries in procurement maturity.", "rating": 8}
{"question": "What are the key characteristics of successful transformations in medtech companies?", "answer": "Leaders are highly involved in network design, teams are cross-functional, a fact-based but rapid approach is deployed, and the team is championed by senior leaders with authority to make adjustments.", "rating": 9}
{"question": "What are the benefits of successful transformations in medtech companies?", "answer": "Cost reductions of 15 to 25 percent, improved service levels, and resilience.", "rating": 8}
{"question": "What is the 'smart quality' framework in medtech companies?", "answer": "A framework that encompasses advanced technologies, modern process design techniques, and flexible ways of working, including five building blocks: smart quality controls, smart quality assurance, process and product mastery, smart quality ways of working, and smart compliance foundation.", "rating": 9}
{"question": "What are the benefits of implementing the 'smart quality' framework?", "answer": "50\u2013100% increase in productivity and speed, 25\u201340% increase in productivity and speed for key quality assurance processes, 30% increase in yield, 80% decrease in deviations and nonconformances, 25% decrease in cost in services and repair, and higher employee satisfaction.", "rating": 9}
{"question": "What is the most important enabler for medtech companies to achieve operational excellence?", "answer": "A medtech company's talent strategy.", "rating": 7}
{"question": "What is the potential impact of a smart quality system on EBITDA and time to market?", "answer": "A tangible influence on EBITDA and acceleration of time to market by more than 30 percent.", "rating": 8}
{"question": "What percentage of medtech companies' outstanding shares are owned by ESG funds?", "answer": "1 to 12 percent.", "rating": 8}
{"question": "What is the impact of being a top-tier ESG performer on the weighted average cost of capital according to Societe Generale?", "answer": "Up to 0.6 percentage points better than that offered to bottom-tier performers.", "rating": 9}
{"question": "What percentage of operations executives believed there was a skills gap in the workforce in a 2020 survey?", "answer": "28 percent.", "rating": 8}
{"question": "What percentage of operations executives believed they would see a skills gap within one to three years in a 2020 survey?", "answer": "58 percent.", "rating": 8}
{"question": "What is the primary enabler for a medtech company to achieve the next level of operational excellence?", "answer": "A talent strategy.", "rating": 7}
{"question": "By how much can adopting certain strategies improve manufacturing and supply chain capacity and responsiveness?", "answer": "20 to 30 percent.", "rating": 10}
{"question": "What percentage of outstanding shares of the top 30 medtech companies by market cap are owned by ESG funds?", "answer": "Anywhere from 1 to 12 percent.", "rating": 10}
{"question": "How does Societe Generale reward top-tier ESG performers in terms of weighted average cost of capital?", "answer": "With a weighted average cost of capital that is up to 0.6 percentage points better than that offered to bottom-tier performers.", "rating": 10}
{"question": "What percentage of the purchasing decision has been assigned to ESG criteria in tenders at Karolinska University Hospital in Stockholm, Sweden?", "answer": "As much as 35 percent.", "rating": 10}
{"question": "What is the National Health Service (NHS) in England committed to achieving by 2045 with respect to goods and services from suppliers?", "answer": "Net-zero emissions.", "rating": 9}
{"question": "What percentage of tenders in Germany have included ESG criteria in the last five years?", "answer": "As many as 55 percent.", "rating": 8}
{"question": "What percentage of employees in the United States consider a company's social and environmental commitments when deciding where to work?", "answer": "58 percent.", "rating": 9}
{"question": "Why do hospital buyers and device manufacturers attribute ESG's limited influence in tender processes?", "answer": "To a lack of differentiation among medtech devices.", "rating": 8}
{"question": "Why have ESG considerations had limited influence in tender processes for medtech devices?", "answer": "Because there is a lack of differentiation among medtech devices.", "rating": 9}
{"question": "What proportion of national greenhouse-gas emissions do healthcare systems account for in most industrialized nations?", "answer": "Close to 10 percent.", "rating": 8}
{"question": "What would be the ranking of the global healthcare sector as a GHG emitter if it were a country?", "answer": "The fifth-largest GHG emitter on the planet.", "rating": 9}
{"question": "What is the first step for companies to reduce their greenhouse-gas emissions?", "answer": "Creating a marginal abatement cost curve (MACC).", "rating": 7}
{"question": "What does the MACC provide to companies?", "answer": "A top-down view of potential investments in decarbonization levers that could reduce an organization's emissions.", "rating": 8}
{"question": "How do companies prioritize decarbonization levers using the MACC?", "answer": "By ranking them in ascending order of cost per metric ton of abated carbon.", "rating": 9}
{"question": "What percentage of a product's resource footprint is established in the R&D phase?", "answer": "Up to 80 percent.", "rating": 9}
{"question": "What percentage of total industry emissions are Scope 3 emissions?", "answer": "60 to 70 percent.", "rating": 9}
{"question": "What is one way medtech companies can decarbonize Scope 3 emissions?", "answer": "Through supplier collaboration and development of new materials.", "rating": 8}
{"question": "What percentage of emissions could be abated with actions that have a positive net present value?", "answer": "About 15 to 25 percent.", "rating": 9}
{"question": "What are some examples of actions that can help abate emissions with a positive net present value?", "answer": "Addressing product packaging, reducing use of plastics containing acrylonitrile butadiene styrene, buying zero-carbon aluminum, instituting closed-loop recycling, switching to 100 percent recycled cardboard, and using battery-powered electric vehicles (BEVs) for transport.", "rating": 10}
{"question": "What are three areas where companies pursue environmental improvements?", "answer": "Design products and packaging for sustainability, decarbonize Scope 3 emissions through supplier collaboration and development of new materials, and build capabilities in marketing and sales.", "rating": 9}
{"question": "What are some actions medtech companies are taking to reduce their environmental impact?", "answer": "Actions include addressing product packaging, reducing use of plastics containing acrylonitrile butadiene styrene, buying zero-carbon aluminum, instituting closed-loop recycling, switching to 100 percent recycled cardboard, and using battery-powered electric vehicles (BEVs) for transport.", "rating": 9}
{"question": "What is the purpose of implementing a data collection, management, and reporting system in medtech companies?", "answer": "To readily access sustainability data for use in responding to tenders.", "rating": 7}
{"question": "What are Scope 3 emissions considered to stem from?", "answer": "Upstream suppliers and their tier-n suppliers, which are purchased goods and services, capital goods, upstream transportation and distribution, and downstream transportation and distribution.", "rating": 9}
{"question": "How many medtech companies have committed to or set science-based targets in the last three years?", "answer": "35 medtech companies have committed to or set science-based targets in the last three years.", "rating": 8}
{"question": "What is the growth rate of medtech companies setting emissions targets?", "answer": "+95% per annum.", "rating": 8}
{"question": "What is the purpose of marginal abatement cost curves (MACC) in medtech companies?", "answer": "To establish a pathway to net-zero emissions.", "rating": 7}
{"question": "What is a major health inequity mentioned in the text?", "answer": "A significant mismatch between commercially available devices and disease burden in low- and middle-income countries (LMICs).", "rating": 9}
{"question": "What percentage of commercially available devices address noncommunicable diseases (NCDs) in low- and middle-income countries?", "answer": "Less than 15 percent.", "rating": 8}
{"question": "What is required for net-zero targets?", "answer": "Validation of both near- and long-term targets.", "rating": 8}
{"question": "What is a significant mismatch in low- and middle-income countries (LMICs)?", "answer": "There is a significant mismatch between commercially available devices and disease burden.", "rating": 8}
{"question": "What percentage of commercially available devices address noncommunicable diseases (NCDs) in low- and middle-income countries?", "answer": "Less than 15 percent.", "rating": 8}
{"question": "What was found in a study of racial bias in pulse oximetry in the United States?", "answer": "Pulse oximetry devices failed to detect occult hypoxemia in Black patients three times more frequently than in White patients.", "rating": 9}
{"question": "In what two areas are leading medtech companies implementing health equity strategies?", "answer": "Democratizing access and affordability of products, and embedding health equity into pipeline development.", "rating": 9}
{"question": "What do leading medtech companies consider when designing and testing products?", "answer": "Ethnicity, age, gender, height, weight, pathological background, socioeconomics, geography, language, and accessibility.", "rating": 9}
{"question": "What percentage of entry-level employees in medtech are women?", "answer": "56 percent.", "rating": 8}
{"question": "What percentage of C-suite leaders in medtech are women?", "answer": "28 percent.", "rating": 8}
{"question": "What percentage of medtech leadership roles in the United States are held by Black people?", "answer": "3 percent.", "rating": 8}
{"question": "What is the percentage of the US population that is Black?", "answer": "More than 13 percent.", "rating": 8}
{"question": "What is the goal for women in management positions globally set by best-in-class medtech diversity leaders?", "answer": "45 percent or more within five years.", "rating": 9}
{"question": "What is the goal for people from ethnically diverse groups in management positions globally set by best-in-class medtech diversity leaders in the United States?", "answer": "30 percent or more within five years.", "rating": 8}
{"question": "Companies in the top quartile for gender diversity on executive teams were how much more likely to have above-average profitability than companies in the bottom quartile?", "answer": "25 percent more likely.", "rating": 9}
{"question": "What percentage of management positions globally are best-in-class medtech diversity leaders aiming to fill with women within five years?", "answer": "45 percent or more.", "rating": 9}
{"question": "What is required for a company to address inclusion?", "answer": "An organization needs to enable equity of opportunity through fairness and transparency; promote openness by tackling bias and discrimination; and foster belonging through support for all kinds of diversity.", "rating": 10}
{"question": "What is the role of sponsors and allies in advancing and retaining diverse talent?", "answer": "Sponsors and allies play a critical role alongside policies and programs.", "rating": 7}
{"question": "What are the three steps to deliver on ESG ambitions?", "answer": "Define the company\u2019s contribution, engage broadly, and sustain the ESG commitment.", "rating": 9}
{"question": "How will medtech leaders likely view ESG in the future?", "answer": "Either as a set of far-off compliance regulations or as an opportunity to create new positive impact and as a source of differentiation.", "rating": 8}
{"question": "How much has the medtech industry grown since 2012?", "answer": "The medtech industry has grown by 50 percent since 2012.", "rating": 8}
{"question": "What can M&A help medtech organizations achieve?", "answer": "M&A can help organizations serve more patients in more ways, enabling them to access new patient pools, scale for better commercial operations, divest distracting and underfunded businesses, and add new capabilities in digital or R&D.", "rating": 9}
{"question": "Why is earnings growth increasingly important to company valuations?", "answer": "Earnings growth is increasingly important to company valuations because it shrinks the pool of attractive potential targets to companies that have the right combination of growth and profitability.", "rating": 9}
{"question": "What is happening to valuations for high-growth medtech targets?", "answer": "Valuations for the highest-growth targets have retreated to their lowest point since 2018.", "rating": 9}
{"question": "How have valuations for high-growth small-cap and midcap medtechs changed from 2018 to 2022?", "answer": "The 1-year forward revenue multiple for high-growth small-cap and midcap medtechs decreased from 11.7\u00d7 in 2018 to 6.3\u00d7 in 2022.", "rating": 9}
{"question": "What is the current trend in valuations for high-growth medtech targets?", "answer": "Valuations for the highest-growth targets have retreated to their lowest point since 2018.", "rating": 9}
{"question": "Why are divesting companies likely to attract many willing buyers?", "answer": "Because of a sedate IPO market, divesting companies are likely to attract many willing buyers in both private and public equity markets.", "rating": 8}
{"question": "How many medtech companies debuted in the public markets in 2022?", "answer": "Only five medtech companies debuted in the public markets in 2022.", "rating": 9}
{"question": "What has risen in importance to prospective buyers in medtech M&A?", "answer": "Profitability (or the ability to increase it) has risen in importance to prospective buyers.", "rating": 9}
{"question": "How did medtech M&A perform during the recessions of 2001 and 2008?", "answer": "Medtech M&A dropped by 20 percent during the recessions of 2001 and 2008.", "rating": 7}
{"question": "How much dry powder do the 30 largest medtech companies currently hold?", "answer": "The 30 largest medtech companies currently hold more than $200 billion of dry powder in cash or cash equivalents.", "rating": 9}
{"question": "What is the impact of weighing profitability more heavily on the number of viable targets?", "answer": "Weighing profitability more heavily culls the number of viable targets.", "rating": 9}
{"question": "How has the importance of margin expansion changed in company valuations since 2019?", "answer": "Margin expansion is now more than twice as important to company valuations as it was in 2019.", "rating": 9}
{"question": "How much dry powder in cash or cash equivalents do the 30 largest medtech companies currently hold?", "answer": "More than $200 billion.", "rating": 8}
{"question": "How many of the 125 largest US- and EU-based medtech companies are high growth and offer potentially accretive margins?", "answer": "Less than a quarter (27).", "rating": 9}
{"question": "What is the result of capping the size of the target at $20 billion in terms of the number of viable medtech companies?", "answer": "The hypothetical target list shrinks to 20.", "rating": 9}
{"question": "What is the median EBITDA margin difference between the 20 largest medtech companies by revenue and the next largest 20?", "answer": "Nearly 11 points.", "rating": 8}
{"question": "What are the two factors that may change the importance and role of large deals in the medtech industry?", "answer": "The rising importance of margin improvement relative to valuations and the evolving relationship between medtech companies and their customers.", "rating": 9}
{"question": "How can large deals benefit medtech companies?", "answer": "Large deals can provide scale, improve companies' cost positions, and integrate offerings across portfolios, making it more likely that a health system will designate a medtech company as a partner of choice.", "rating": 9}
{"question": "What is the median EBITDA margin difference between the 20 largest medtech companies by revenue and the next largest 20?", "answer": "Nearly 11 points.", "rating": 8}
{"question": "Why did two midsize orthopedics companies recently merge?", "answer": "In part to use their newfound scale to provide higher service levels to customers.", "rating": 7}
{"question": "What is the purpose of programmatic M&A in the medtech industry?", "answer": "To achieve specific corporate objectives through a strategic series of deals.", "rating": 9}
{"question": "How can M&A help medtech companies with digital innovation?", "answer": "M&A can help companies transform their digital innovation prospects and 'short-circuit' yearslong development cycles.", "rating": 8}
{"question": "What type of acquisitions might be more valuable for medtech companies?", "answer": "Growth-focused acquisitions that expand the core.", "rating": 8}
{"question": "Why will acquiring companies likely want to prepare strategies in acquisitions that target specific innovations or new capabilities?", "answer": "To mitigate potential margin dilution.", "rating": 8}
{"question": "How did the public markets react to a 2023 programmatic acquisition in AI imaging equipment and software?", "answer": "The public markets reacted favorably to it, as it boosted the combined entity\u2019s growth trajectory and its ability to use its scale to forge and maintain customer relationships.", "rating": 8}
{"question": "What is one reason companies are exploring non-traditional transaction structures in M&A?", "answer": "To reduce their own profit-and-loss or capital constraints by sharing costs with or shifting them to outside partners.", "rating": 9}
{"question": "What is an example of a non-traditional transaction structure used in the medtech industry?", "answer": "Blackstone Life Sciences announced a $337 million product investment in Medtronic to expand development of diabetes technologies.", "rating": 9}
{"question": "Why are divestitures becoming more common in the medtech industry?", "answer": "Because many companies now have large, diverse, and unwieldy portfolios, making it difficult to find strategic moves that materially alter their trajectories.", "rating": 8}
{"question": "What has happened to medtech divestiture value since 2019?", "answer": "Divestitures have nearly tripled since 2019.", "rating": 7}
{"question": "How much new revenue would a company with $10 billion in annual sales need to generate to keep pace with market growth?", "answer": "$500 million to $600 million.", "rating": 8}
{"question": "How have medtech divestitures changed since 2019?", "answer": "Divestitures have nearly tripled since 2019.", "rating": 8}
{"question": "What percentage of global revenue do the five largest medtech MNCs generate from China?", "answer": "An aggregate 10 to 15 percent.", "rating": 8}
{"question": "Why are divestitures beneficial for companies?", "answer": "Divestitures can relieve companies of segments with lower strategic or financial value, freeing management to concentrate on the core business, and the proceeds can fund potential acquisitions or growth initiatives.", "rating": 9}
{"question": "What is the trend in medtech divestitures as of 2022?", "answer": "Medtech companies sold off almost three times as much business (as measured by value) in 2022 as they had in 2019.", "rating": 9}
{"question": "What is the significance of China for medtech multinational companies?", "answer": "China is the second-largest and fastest-growing medtech market globally and has become a top contributor to the overall growth of some MNCs.", "rating": 9}
{"question": "How much new revenue would a company with $10 billion in annual sales need to generate to keep pace with market growth?", "answer": "$500 million to $600 million.", "rating": 8}
{"question": "How have medtech divestitures changed since 2019?", "answer": "Divestitures have nearly tripled since 2019.", "rating": 8}
{"question": "What percentage of global revenue do the five largest medtech MNCs generate from China?", "answer": "An aggregate 10 to 15 percent.", "rating": 8}
{"question": "Why are divestitures beneficial for companies?", "answer": "Divestitures can relieve companies of segments with lower strategic or financial value, freeing management to concentrate on the core business, and the proceeds can fund potential acquisitions or growth initiatives.", "rating": 9}
{"question": "What is the trend in medtech divestitures as of 2022?", "answer": "Medtech companies sold off almost three times as much business (as measured by value) in 2022 as they had in 2019.", "rating": 9}
{"question": "What is the significance of China for medtech multinational companies?", "answer": "China is the second-largest and fastest-growing medtech market globally and has become a top contributor to the overall growth of some MNCs.", "rating": 9}
{"question": "What percentage of global revenue do the five largest medtech MNCs generate from China?", "answer": "10 to 15 percent.", "rating": 8}
{"question": "What percentage of a large global medical-imaging company's global ultrasound units are produced in China?", "answer": "40 percent.", "rating": 8}
{"question": "What is the main goal of Volume-based procurement (VBP) in China?", "answer": "Lowering unit prices through centralized tendering.", "rating": 9}
{"question": "By what percentage have VBP tenders reduced prices in hospitals?", "answer": "50 to 90 percent.", "rating": 8}
{"question": "What is the expected coverage of diagnosis-related groups (DRGs) and diagnosis intervention packages (DIPs) under basic medical insurance spending by 2025?", "answer": "70 percent.", "rating": 9}
{"question": "What industrial policy is putting pressure on MNCs to localize in China?", "answer": "Made in China 2025.", "rating": 9}
{"question": "By when will DRGs and DIPs be implemented in all hospitals and cover 70 percent of basic medical insurance spending?", "answer": "2025.", "rating": 8}
{"question": "What is the impact of DRGs and DIPs on hospitals' product choices?", "answer": "Hospitals are more likely to choose lower-priced products to control costs.", "rating": 9}
{"question": "What is the aim of the Made in China 2025 industrial policy and the dual-circulation strategy?", "answer": "Advancing domestic manufacturing capabilities in high-tech, high-value industries, including medtech.", "rating": 9}
{"question": "How have Chinese medtech companies performed in certain categories?", "answer": "They have launched products first in China, such as transcatheter aortic valve replacements, and captured market share across categories, with over 50 percent market share in medical imaging and many types of orthopedic and cardiovascular devices.", "rating": 9}
{"question": "What are the expectations of medtech GMs regarding their China businesses?", "answer": "They expect quick postpandemic recovery and solid growth in the high single digits for their China businesses in the next few years.", "rating": 9}
{"question": "Do medtech MNCs plan to scale back their China businesses?", "answer": "No, none of the 20 medtech GMs surveyed reported plans to scale back their China businesses.", "rating": 10}
{"question": "What growth rate do medtech GMs expect for their China businesses in the next few years?", "answer": "High single digits.", "rating": 8}
{"question": "How many medtech GMs expect continued investments into China from their parent company?", "answer": "14 out of 20.", "rating": 9}
{"question": "What is the projected growth rate of China's medtech market from 2021 to 2030?", "answer": "5 to 10 percent CAGR.", "rating": 9}
{"question": "What will be the size of China's medtech market by 2030?", "answer": "$110 billion to $165 billion.", "rating": 9}
{"question": "What was the total market capitalization of publicly listed Chinese medtech companies in 2022?", "answer": "$355 billion.", "rating": 8}
{"question": "Why is an ongoing presence in China essential for MNCs?", "answer": "To secure access to innovation and manufacturing capabilities.", "rating": 8}
{"question": "What happened to the number of private equity and venture capital investments in medtech in Greater China between 2017 and 2021?", "answer": "It grew from about 200 to 330.", "rating": 8}
{"question": "What was the cumulative deal value of private equity and venture capital investments in medtech in Greater China in 2021?", "answer": "About $3.4 billion.", "rating": 8}
{"question": "What are the two questions that medtech MNCs should ask when reviewing their strategic options in China?", "answer": "What are the stakes in China for the global business? And how well is the business positioned to succeed in China in the future?", "rating": 9}
{"question": "What is the projected growth of the medtech market in China from 2021 to 2030?", "answer": "The medtech market in China is projected to double from 2021 to 2030.", "rating": 8}
{"question": "What are the four courses of action for MNCs to define their strategic posture in China?", "answer": "The four courses of action are: Selectively accelerating, Renewing commitments, Reducing stakes, and Diversifying.", "rating": 9}
{"question": "What does 'Selectively accelerating' entail for MNCs in China?", "answer": "Selectively accelerating involves adopting an asset-light model to expand business in China in attractive segments or focusing on a part of the global portfolio that is competitive in China.", "rating": 9}
{"question": "What is 'Renewing commitments' for MNCs in China?", "answer": "Renewing commitments involves expanding the value of the company\u2019s global business model in China, with local adaptations, such as localizing production and value chains.", "rating": 9}
{"question": "How have medtech deal volume and deal values changed in China?", "answer": "Medtech deal volume and deal values have grown in China.", "rating": 7}
{"question": "Along what two dimensions can multinational companies in China evaluate themselves?", "answer": "Multinational companies in China can evaluate themselves along the dimensions of 'Current value at stake in China' and 'Future right to win in China'.", "rating": 9}
{"question": "How have medtech deal volume and deal values changed in China from 2017 to 2022?", "answer": "Medtech deal volume and deal values have grown in China from 2017 to 2022.", "rating": 8}
{"question": "What are the two dimensions along which multinational companies in China can evaluate themselves?", "answer": "Multinational companies in China can evaluate themselves along two dimensions: 'Current value at stake in China' and 'Future right to win in China'.", "rating": 9}
{"question": "What are the four strategic options for multinational companies in China based on the two dimensions?", "answer": "The four strategic options are: 'Renewing commitments', 'Selectively accelerating', 'Reducing stakes', and 'Diversifying'.", "rating": 9}
{"question": "What does 'Renewing commitments' involve for companies heavily invested in China?", "answer": "Renewing commitments involves staying heavily invested in China and doubling down on capital investments as necessary.", "rating": 9}
{"question": "Why is strategic decision making difficult for companies operating in China?", "answer": "Strategic decision making is difficult partly because of the fast-moving market context and because many leaders have had decades of experience with China as a reliable all-around growth market.", "rating": 8}
{"question": "What is required for medtech MNCs to adjust to their updated China strategies?", "answer": "Fact-based and trusting conversations between global and local leadership.", "rating": 8}
{"question": "What are medtech MNCs striving to achieve as they revisit their China strategies?", "answer": "A balance that allows them to tap into current and future opportunities while managing uncertainties.", "rating": 8}
{"question": "What is one way that China's contributions to a medtech MNC's business can be interdependent?", "answer": "Product volumes destined for the China market can affect the cost of goods sold (COGS), making supply chains deeply intertwined with China-based manufacturing sites and suppliers.", "rating": 9}
{"question": "How has VBP affected certain product categories in China?", "answer": "VBP has catapulted some product categories into commoditization and eroded the attractiveness of others due to local competition.", "rating": 8}
{"question": "Why might a medtech company consider licensing parts of its portfolio to a local distributor?", "answer": "Because commoditized products may be margin dilutive from an MNC's point of view, but a local distributor with a different commercial model might generate economic value from them.", "rating": 9}
{"question": "Why should medtech leaders consider local partners in China?", "answer": "To achieve business objectives, as the market has evolved to include a broader customer base, a vibrant local industry, and a rapidly evolving digital ecosystem.", "rating": 8}
{"question": "What are some potential partnership models for medtech companies in China?", "answer": "Asset-level licensing, complementary portfolios, and joint ventures that provide funding and market access.", "rating": 9}
{"question": "How is China contributing to medtech innovation?", "answer": "China is increasingly becoming a center of medtech innovation, with products invented in China available for licensing, Chinese medtech companies being potential M&A candidates, and a thriving digital ecosystem with innovations in consumer health platforms and remote healthcare.", "rating": 9}
{"question": "What is an example of a medtech MNC acquiring a Chinese company?", "answer": "Boston Scientific acquired a majority stake in Acotec in 2022, incorporating a locally made portfolio of cardiovascular intervention devices.", "rating": 8}
{"question": "What is required for medtech MNCs to operate efficiently in China?", "answer": "Transforming the traditional high-touch model into one that emphasizes efficiency and agility and leverages omnichannel engagement.", "rating": 8}
{"question": "Why is it important for medtech MNCs to stay up to date on evolving policy frameworks in China?", "answer": "To ensure regulatory compliance with evolving data privacy and data security laws, local manufacturing guidelines, procurement policies, and pricing and reimbursement policies.", "rating": 9}
{"question": "What is the expected status of China's medtech market in the world?", "answer": "China will continue to be the second-largest medtech market in the world.", "rating": 9}
{"question": "What is the current state of the regulatory framework for local manufacturing and procurement guidelines in China?", "answer": "The regulatory framework for local manufacturing, local procurement guidelines, and pricing and reimbursement policies continues to evolve.", "rating": 9}
{"question": "What is China's position in the global medtech market?", "answer": "China will continue to be the second-largest medtech market in the world.", "rating": 9}
{"question": "What is required for medtech companies to succeed in China?", "answer": "Success is more likely to come to those that act quickly.", "rating": 7}
{"question": "When was the report 'Medtech Pulse: Thriving in the next decade' published?", "answer": "September 2023", "rating": 8}
